Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration

Expert Opinion on Emerging Drugs

Volumn 10, Issue 1, 2005, Pages 119-135

  Comer, Grant M ^b   Ciulla, Thomas A ^a   Heier, Jeffery S ^c   Criswell, Mark H ^b  

^a MIDWEST EYE INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

Author keywords

Age Related Eye Disease Study (AREDS); Age related macular degeneration; Choroidal neovascular membrane; Macular Photocoagulation Study (MPS); Photodynamic therapy; Thermal laser photocoagulation; Treatment of AMD with PDT (TAP) study

Indexed keywords

ADENOVIRUS VECTOR; ALPHA TOCOPHEROL; ANECORTAVE; ANTIOXIDANT; ASCORBIC ACID; ATX S10; ATXS 10; BENZOPORPHYRIN DERIVATIVE; BETA CAROTENE; CAND 5; CAROTENOID; CELECOXIB; COMBRETASTATIN A4 PHOSPHATE; CONJUGATED VERTEPORFIN; COPPER; FLUORESCEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICAPS; LUTETIUM TEXAPHYRIN; MODIFIED VISUDYNE; OCUVITE PRESERVISION; PEGAPTANIB; PHOTOSENSITIZING AGENT; PHOTREX; PIGMENT EPITHELIUM DERIVED FACTOR; PRINOMASTAT; RANIBIZUMAB; ROSTAPORFIN; SIRNA 027; SQUALAMINE; TALAPORFIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISAGEN; XANTHOPHYLL; ZEAXANTHIN; ZINC;

ANTIOXIDANT ACTIVITY; BACKACHE; CATARACT; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG TOLERABILITY; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; HEART PALPITATION; HUMAN; HYPERTENSION; INDUSTRIALIZATION; INJECTION SITE REACTION; INTRAOCULAR HYPERTENSION; LASER COAGULATION; NONHUMAN; PHOTODYNAMIC THERAPY; PREVENTIVE MEDICINE; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; SPECTRAL SENSITIVITY; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

ANTIOXIDANTS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; MACULAR DEGENERATION; MACULAR EDEMA, CYSTOID; PHOTOCHEMOTHERAPY;

EID: 14344262404     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.10.1.119     Document Type: Review

References (153)

1. KAHN H, LEIBOWITZ H, GANLEY J et al.: The Framingham eye study. I. Outline and major prevalence findings. Am. J. Epidemiol. (1977) 106:17-41.
2. ATTEBO K, MITCHELL P, SMITH W: Visual acuity and the causes of visual loss in Australia: the Blue Mountains Eye Study. Ophthalmology (1996) 103:357-364.
3. KLAVER D, WOLFS R, VINGERLING J et al.: Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam study. Arch. Ophthalmol. (1998) 116:653-658.
4. TIELSCH J, JAVITT J, COLEMAN A et al.: The prevalence of blindness and visual impairment among nursing home residents in Baltimore. N. Engl. J. Med. (1995) 332:1205-1209.
5. SEDDON J. Epidemiology of age-related macular degeneration. St. Louis: Mosby, (2001) 1039-1050.
6. BIRD A, BRESSLER N, BRESSLER S et al.: An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv. Ophthalmol. (1995) 39:367-374.
7. AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. (2001) 119:1417-1436.
8. FLIESLER S, ANDERSON R: Chemistry and metabolism of fluids in the vertebrate retina. Prog. Lipid Res. (1983) 22:79-131.
9. GERSTER H: Review: antioxidant protection of the aging macula. Age Aging (1991) 112:60-69.
10. YOUNG R: Solar radiation and age-related macular degeneration. Surv. Ophthalmol. (1988) 32:252-269.
11. BEATTY S, KOH H, PHIL M et al.: The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. (2000) 45:115-134.
12. NEWSOME D, SWARTZ M, LEONE N et al.: Oral zinc in macular degeneration. Arch. Ophthalmol. (1988) 106:192-198.
13. THE ALPHA TOCOPHEROL BETA CAROTENE CANCER PREVENTION STUDY GROUP: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. (1994) 330:1029-1035.
14. MACULAR PHOTOCOAGULATION STUDY GROUP: Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch. Ophthalmol. (1991) 109:1109-1114.
15. MACULAR PHOTOCOAGULATION STUDY GROUP: Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch. Ophthalmol. (1993) 111:1189-1199.
16. MACULAR PHOTOCOAGULATION STUDY GROUP: Argon laser photocoagulation for senile macular degeneration. Arch. Ophthalmol. (1982) 100:912-923.
17. MACULAR PHOTOCOAGULATION STUDY GROUP: Argon laser photocoagulation for neovascular maculopathy; Three-year results from randomized clinical trials. Arch. Ophthalmol. (1986) 104:694-701.
18. FREUND K, YANNUZZI L, SORENSON J: Age-related macular degeneration and choroidal neovascularization. Am. J. Ophthalmol. (1993) 115:786-791.
19. MOISSEIEV J, ALHALEL A, MASURI R, TREISTER G: The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch. Ophthalmol. (1995) 113:185-189.
20. MACULAR PHOTOCOAGULATION STUDY GROUP: Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch. Ophthalmol. (1986) 104:503-512.
21. MACULAR PHOTOCOAGULATION STUDY GROUP: Subfoveal neovascular lesions in age-related macular degeneration; guidelines for evaluation and treatment in the macular photocoagulation study. Arch. Ophthalmol. (1991) 109:1242-1257.
22. MACULAR PHOTOCOAGULATION STUDY GROUP: Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Arch. Ophthalmol. (1993) 111:1200-1209.
23. AVELINE B, HASEN T, RENARD R: Photochemical and photosensitizing properties of BPD-MA. Photochem. Photobiol. (1994) 59:328-335.
24. HUNT D, JIANG H, GRANVILLE D et al.: Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes. Immunopharmacology (1999) 41:31-44.
25. ALLISON B, WATERFIELD E, RICHTER A, LEVY J: The effects of plasma lipoproteins on in vivo tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. Photochem. Photobiol. (1991) 54:709-715.
26. REICHEL E, PULIAFITO C, DUKER J, GUYER D: Indocyanine green dye-enhanced diode laser photocoagulation of poorly defined subfoveal choroidal neovascularization. Ophthalmic. Surg. (1994) 25:195-201.
27. HOPE-ROSS M, GIBSON J, CHELL P et al.: Dye enhanced laser photocoagulation in the treatment of a peripapillary subretinal neovascular membrane. Acta. Ophthalmol. (1994) 72:134-137.
28. MORIARTY A: Indocyanine green enhanced diode laser photocoagulation of subretinal neovascular membranes Br. J. Ophthalmol. (1994) 1994:238-239.
29. TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY (TAP) STUDY GROUP: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch. Ophthalmol. (1999) 117:1329-1345.
30. TREATMENT Of AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY (TAP) STUDY GROUP: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch. Ophthalmol. (2001) 119:198-207.
31. TREATMENT Of AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY (TAP) STUDY GROUP: Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP Report 5. Arch. Ophthalmol. (2002) 120:1307-1314.
32. VERTEPORFIN IN PHOTODYNAMIC THERAPY (VIP) STUDY GROUP: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2. Am. J. Ophthalmol. (2001) 131:541-560.
33. BRESSLER N: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularizaation - Verteporfin in Photodynamic Therapy Report 2. Am. J. Ophthalmol. (2002) 133:168-169.
34. NISHIWAKI H, ZEIMER R, GOLDBERG M et al.: Laser targeted photo-occlusion of rat choroidal neovascularization without collateral damage. Photochem. Photobiol. (2002) 75:149-158.
35. GRISANTI S, TATAR O, CANBEK S et al.: Immunohistopathologic evaluation of choroidal neovascular membranes following verteportin photodynamic therapy. Am. J. Ophthalmol. (2004) 137:914-923.
36. BONE R, LANDRUM J, TARSIS S: Preliminary identification of the human macular pigment. Vision Res. (1985) 25:1531-1535.
37. BONE R, LANDRUM J, HIME G et al.: Stereochemistry of the human macular pigment. Invest Ophthalmol. Vis. Sci. (1993) 34:2033-2040.
38. MALINOW M, FEENEY-BURNS L, PETERSON L et al.: Diet-related macular anomalies in monkeys. Invest Ophthalmol. Vis. Sci. (1980) 19:857-863.
39. NEURINGER M, KLEIN M, SNODDERLY M et al.: Effects of carotenoid depletion and N-3 fatty acid status on macular defects in Rhesus monkeys. Invest Ophthalmol. Vis. Sci. (1999) 40(S164):Abstract 842.
40. CIULLA T, CURRAN-CELANTANO J, COOPER D et al.: Macular pigment optical density in a midwestern sample. Ophthalmology (2001) 108:730-737.
41. SCHALCH W: Carotenoids in the retina - a review of their possible role to prevent or limit damage by light and oxygen. Free Radicals and Aging (1992) 62:280-298.
42. SNODDERLY D, AURAN J, DELORI F: The macular pigment. II. Spatial distribution in primate retinas. Invest Ophthalmol. Vis. Sci. (1984) 25:674-685.
43. KATZ M, PARKER K, HANDELMAN G et al.: Effects of antioxidant nutrient deficiency on the retina and retinal pigment epithelium of albino rats: A light and electron microscopic study. Exp. Eye Res. (1982) 34:339-369.
44. SEDDON J, HENNEKES C: Vitamins, minerals, and macular degeneration: Promising but unproven hypotheses. Arch. Ophthalmol. (1994) 112:176-178.
45. SEDDON J, AJANI U, SPERDUTO R et al.: Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA (1994) 272:1413-1420.
46. WEST S, VITALE S, HALLFRISCH J et al.: Antioxidants and supplements: Protective for age-related macular degeneration. Arch. Ophthalmol. (1994) 112:222-227.
47. GALE C, HALL N, PHILLIPS D, MARTYN C: Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest Ophthalmol. Vis. Sci. (2003) 44:2461-2465.
48. HAMMOND BJ, CIULLA T, SNODDERLY D: Macular pigment density is reduced in obese subjects. Invest Ophthalmol. Vis. Sci. (2002) 43:47-50.
49. SEDDON J, COTE J, DAVIS N, ROSNER B: Progression of age-related macular degeneration association with body mass index, waist circumference, and waist-hip ratio. Arch. Ophthalmol. (2003) 121:785-792.
50. MARES-PERLMAN J, BRANDY W, KLEIN R et al.: Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch. Ophthalmol. (1995) 113:1518-1523.
51. CHEW E: Age Related Eye Disease Study Research Group. Micronutrient supplementation. American Academy of Ophthalmology Annual Meeting (2004) New Orleans, LA; Retina Subspecialty Day supplement:4.
52. CIULLA T, HARRIS A, KAGEMANN L et al.: Choroidal perfusion pertubations in non-neovascular age related macular degeneration. Br. J. Ophthalmol. (2002) 86:209-213.
53. CIULLA T, HARRIS A, MARTIN B: Ocular perfusion and age-related macular degeneration. Acta. Ophthalmol. Scand. (2001) 79:108-115.
54. CIULLA T, HARRIS A, CHUNG H et al.: Color Doppler imaging discloses reduced ocular blood flow velocities in nonexudative age-related macular degeneration. Am. J. Ophthalmol. (1999) 128:75-80.
55. FRIEDMAN E, KRUPSKY S, LANE A et al.: Ocular blood flow velocity in age-related macular degeneration. Ophthalmology (1995) 102:640-646.
56. FRIEDMAN E: A hemodynamic model of the pathogenesis of age-related macular degeneration. Am. J. Ophthalmol. (1997) 124:677-682.
57. BOKER T, FANG T, STEINMETZ R: Refractive error and choroidal perfusion characteristics in patients with choroidal neovascularization and age-related macular degeneration. Ger. J. Ophthalmol. (1993) 2:10-13.
58. REMULLA J, GAUDIO A, MILLER S, SANDBERG M: Foveal electroretinograms and choroidal perfusion characteristics in fellow eyes of patients with unilateral neovascular age-related macular degeneration. Br. J. Ophthalmol. (1995) 79:558-561.
59. ZHAO J, FRAMBACH D, LEE P et al.: Delayed macular choriocapillary circulation in age-related macular degeneration. Int. Ophthalmol. (1995) 19:1-12.
60. WIDDER R, BRUNNER R, ENGELS B et al.: Changes of hemorheological and biochemical parameters after plasma perfusion using a tryptophan-polyvinyl alcohol adsorber leading to clinical improvement in patients suffering from maculopathy. Blood Purif. (1998) 16:15-21.
61. BRUNNER R, WIDDER R, WALTER P et al.: Change in hemorrheological and biochemical parameters following membrane differential filtration. Int. J. Artif. Organs (1995) 18:794-798.
62. BRUNNER R, WIDDER R, WALTER P et al.: Influence of membrane differential filtration on the natural course of age-related macular degeneration. Retina (2000) 20:483-491.
63. MCGWIN G, OWSLEY C, CURCIO C, CRAIN R: The association between statin use and age related maculopathy. Br. J. Ophthalmol. (2003) 87:1121-1125.
64. WILSON H, SCHWARTZ D, BHATT H et al.: Statin and aspirin therapy are associated with decreased rates of chroroidal neovascularization among patients with age-related macular degeneration. Am. J. Ophthalmol. (2004) 137:615-624.
65. HALL N, GALE C, SYDDALL H et al.: Risk of macular degeneration in users of statins: cross sectional study. BMJ (2001) 323:375-376.
66. MCCARTY C, MUKESH B, GUYMER R et al.: Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. MJA (2001) 175:340.
67. KLEIN R, KLEIN B, TOMANY S et al.: Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch. Ophthalmol. (2003) 121:1151-1155.
68. BRESSLER N, ROSENFELD P, LIM J, VIM STUDY GROUP: A Phase II placebo-controlled, double-masked, randomized trial - verteporfin in minimally classic CNV due to AMD (VIM). Invest Ophthalmol. Vis. Sci. (2003) 44:E-abstract 1100.
69. GONZALEZ J: Visudyne benefits patients with minimally classic lesion at 1 year. Ocular Surgery News (2003):21.
70. ROSENFELD P, VIM STUDY GROUP: Verteporfin in minimally classic CNV due to AMD (VIM) - two-year results from a Phase II controlled clinical trial. Invest Ophthalmol. Vis. Sci. (2004) 45:E-abstract 2273.
71. RIDDLE J: PDT: Therapies on the cutting edge. Jobson's Review of Ophthalmology (2003) X(8):40-46.
72. STUR M, VER STUDY GROUP: Verteporfin Early Retreatment (VER) - 12-month results of a Phase IIIB controlled clinical trial. Invest Ophthalmol. Vis. Sci. (2004) 45:E-abstract 2275.
73. SLAKTER J, ROSENFELD P, VALIO STUDY GROUP: Verteporfin with altered (delayed) light in occult CNV (VALIO) - Results of a Phase II controlled clinical trial. Invest Ophthalmol. Vis. Sci. (2003) 44:E-abstract 1101.
74. SINGERMAN L, ROSENFELD P, VALIO STUDY GROUP: Verteporfin with altered (delayed) light in occult (VALIO) - 12-month results of a Phase II controlled clinical trial. Invest Ophthalmol. Vis. Sci. (2004) 45:E-abstract 2274.
75. PEYMAN G, MOSHFEGHI D, MOSHFEGHI A et al.: Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2). Ophthalmic Surg. Lasers (1997) 28:409-417.
76. MOSHFEGHI D, PEYMAN G, MOSHFEGHI A et al.: Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodymanic therapy: time dependencies. Ophthalmic Surg. Lasers (1998) 29:663-668.
77. REGILLO C: Update on photodynamic therapy. Curr. Opinion Ophthalmol. (2000) 11:166-170.
78. THOMAS E, SnET2 STUDY GROUP: SnET2 photodynamic therapy for age-related macular degeneration: visual acuity efficacy outcomes from two parallel Phase III trials. Invest Ophthalmol. Vis. Sci. (2004) 45:E-abstract 2214.
79. BLUMENKRANZ M, MILLER J, GUYER D et al.: Preliminary results from a Phase II dose-response study of photodynamic therapy with motexafin lutetium to treat subfoveal CNV. Invest Ophthalmol. Vis. Sci. (2000) 41(S531):abstract 2827.
80. OBANA A, GOHTO Y, KANAI M et al.: Selective photodynamic effects of new photosensitizer ATX-S10(Na) on choroidal neovascularization in monkeys. Arch. Ophthalmol. (2000) 118:650-658.
81. RENNO R, TERADA Y, HADDADAIN M et al.: Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch. Ophthalmol. (2004) 122:1002-1011.
82. ISHIBASHI T, MIKI K, SORGENTE N et al.: Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primat. Arch. Ophthalmol. (1985) 103:708-711.
83. KVANTA A: Expression and regulation of vascular endothelial growth factor in choroidal fibroblasts. Curr. Eye Res. (1995) 14:1015-1020.
84. AMIN R, PUKLIN J, FRANK R: Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol. Vis. Sci. (1994) 35:3178-3188.
85. LOPEZ P, SIPPY B, LAMBERT H et al.: Transdifferentiated retinal pigment epithelia cells ate immunoteactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol. Vis. Sci. (1996) 37:855-568.
86. REDDY V, ZAMORA R, KAPLAN H: Distribution of growth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome. Am. J. Ophthalmol. (1995) 120:291-301.
87. YI X, OGATA N, KOMADA M et al.: Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch. Clin. Exp. Ophthalmol. (1997) 235:313-319.
88. OKAMOTO N, TOBE T, HACKETT S et al.: Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am. J. Pathol. (1997) 151:281-291.
89. ADAMIS A, SHIMA D, TOLENTINO M et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. (1996) 114:66-71.
90. AIELLO L, PIERCE E, ED F et al.: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA (1995) 92:10457-10461.
91. THE EYETECH STUDY GROUP: Preclinical and Phase 1a clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. (2002) 22:143-152.
92. THE EYETECH STUDY GROUP: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration - Phase II study results. Ophthalmology (2003) 110:979-986.
93. GRAGOUDAS E: VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1): efficacy redulst from Phase II/III Macugen (pegaptanib sodium) clinical trials [abstract]. Invest Ophthalmol. Vis. Sci. (2004) 45(E-abstract 2364).
94. SCHWARTZ S: Anti-VEGF: Eyetech - Macugen. American Academy of Ophthalmology Annual Meeting (2004) New Orleans, LA; Retina Subspecialty Day supplement:35-7.
95. D'AMICO D, BIRD A: VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1): safety evaluation from the pivotal Macugen™ (pegaptanib sodium) clinical trials [abstract]. Invest Ophthalmol. Vis. Sci. (2004) 45:E-abstract 2363.
96. ROACH L: Macugen ups the anti-AMD ante. Eyenet (2004) :29-30.
97. HEIER J, SY J, MCCLUSKEY E, RHUFAB V2 STUDY GROUP: RhuFab V2 in wet AMD - 6 month continued improvement following multiple intravitreal injections. Invest Ophthalmol. Vis. Sci. (2003) 44:E-abstract 972.
98. HEIER J: Anti-VEGF: Genentech-Ranibizumab. American Academy of Ophthalmology Annual Meeting (2004) New Orleans, LA; Retina Subspecialty Day supplement:38.
99. GUTTMAN C: Phase III study eyes intravitreal therapy for exudative AMD. Ophthalmology Times (2004) 29(13):40-41.
100. HOLASH J, DAVIS S, PAPADOPOULOS N et al.: VEGF-Trap: a VEGF blocker with potent antitumor effects. PNAS (2002) 99:11393-11398.
101. SAISHIN Y, SAISHIN Y, TAKAHASHI K et al.: VEGF-TRAP R1R2 suppresses chroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. Physiol. (2003) 195:241-248.
102. TOLENTINO M, BRUCKER A, FOSNOT J et al.: Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in nonhuman primate laser induced model of choroidal neovascularization. Retina (2004) 24:132-138.
103. REICH S, FOSNOT J, KUROKI A et al.: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. (2003) 9:210-216.
104. HOLEKAMP N, BOUCK N, VOLPERT O: Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am. J. Ophthalmol. (2002) 134:220-227.
105. TAKITA H, YONEYA S, GEHLBACK P et al.: Retinal neuroprotection against ischemic injury mediated by intraocular gene transfer of pigment epithelium derived factor. Invest Ophthalmol. Vis. Sci. (2003) 44:4497-4504.
106. STELLMACH V, CRAWFORD S, ZHOU W, BOUCK N: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc. Natl. Acad. Sci. USA (2001) 98:2593-2597.
107. MORI K, DUH E, GEHLBACK P et al.: Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J. Cell. Invest. (2001) 188:253-263.
108. RASMUSSEN H, CHU K, P C et al.: Clinical protocol. An open-label, Phase I, single administration dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum. Gene Ther. (2001) 12:2029-2032.
109. CAMPOCHIARO P, KLEIN M, HOLTZ E et al.: AdPEDF therapy for subfoveal choroidal neovascularization (CNV): preliminary Phase I results. Invest. Ophthalmol. Vis. Sci. (2004) 45:E-abstract 2361.
110. LEAHY K, ORNBERG R, WANG Y et al.: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. (2002) 62:625-631.
111. GENAIDY M, KAZI A, PEYMAN G et al.: Effect of squalamine on iris neovascularization in monkeys. Retina (2002) 22:772-778.
112. HIGGINS R, SANDERS R, YAN Y et al.: Squalamine improves retinal neovascularization. Invest Ophthalmol. Vis. Sci. (2000) 41:1507-1512.
113. CIULLA T, CRISWELL M, DANIS R et al.: Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina (2003) 23:808-814.
114. WOESNNER J: The matrix metalloproteinase family. Academy Press, San Diego (1998) :1-14.
115. MATRISIAN L. Metalloproteinases and their inhibitors in matrix remodeling: Review. Trends Genet. (1990) 6:121-125.
116. ANAND-APTE B, PEPPER M, VOEST E et al.: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol. Vis. Sci. (1997) 38:817-823.
117. STEEN B, SEJERSEN S, BERGLIN L et al.: Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol. Vis. Sci. (1998) 39:2194-2200.
118. FARIS R, APTE S, OLSEN B et al.: Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am. J. Pathol. (1997) 150:323-328.
119. KAMEI M, HOLLEYFIELD J: TIMP-3 in Bruch's membrane: change during aging and in age-related macular degeneration. Invest Ophthalmol. Vis. Sci. (1999) 40:2367-2375.
120. OZERDEM U, MACH-HOFACRE B, VARKI N et al.: The effect of prinomastat (AG2240), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model. Curr. Eye Res. (2002) 24:86-91.
121. OZERDEM U, MACH-HOFACRE B, KEEFE K et al.: The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res. (2001) 33:20-23.
122. CHENG L, RIVERO M, GARCIA C et al.: Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J. Ocular. Pharm. Ther. (2001) 17:295-304.
123. ZHANG K, MCDERMOTT C, BREKKEN J et al.: Ocular bioavailability and pharmacokinetics of AG3340, a potent MMP inhibitor with antiangiogenic activity, following oral administration. Proc. NY Acad. Sci.. Tampa, FL, (1998).
124. COLLIER M, YUEN B, BANSAL S et al.: Phase I study of the matrix metalloprotease inhibitor AG3340 given in a single dose to healthy volunteers. Proc. Am. Assoc. Cancer Res. (1997) 38:A1491.
125. GARCIA C, BARTSCH D, RIVERO M et al.: Efficacy of prinomastat (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr. Eye Res. (2002) 24:33-38.
126. NAMBU H, NAMBU R, MELIA M, CAMPOCHIARO P: Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. (2003) 44-3650-3655.
127. FOLKMAN J, INGBER D: Angiostatic steroids. Ann. Surg. (1987) 206:374-382.
128. OHKUMA H, RYAN S: Experimental subretinal neovascularization in the monkey. Permeability of new vessels. Arch. Ophthalmol. (1983) 101:1102-1110.
129. SCHLAEGEL T: Ocular Histoplasmosis. Grund & Stratton, New York (1977).
130. MARTIDIS A, MILLER D, CIULLA T et al.: Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J. Ocular. Pharm. Ther. (1999) 15:425-428.
131. CIULLA T, CRISWELL M, DANIS R, HILL T: Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch. Ophthalmol. (2001) 119:399-404.
132. DANIS R, BINGAMAN D, YANG Y, LADD L: Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology (1996) 103:2099-2104.
133. PENFOLD P, GYORY J, HUNYOR A, BILLSON F: Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust. N. Zeal. J. Ophthalmol. (1995) 23:293-298.
134. DANIS R, CIULLA T, PRATT L et al.: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina (2000) 20:244-250.
135. RANSON N, DANIS R, CIULLA T, PRATT L: Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br. J. Ophthalmol. (2002) 86:527-529.
136. CHALLA J, GILLIES M, PENFOLD P et al.: Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust. N. Zeal. J. Ophthalmol. (1998) 26:277-281.
137. GILLIES M, SIMPSON J, LUO W et al.: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration. Arch. Ophthalmol. (2003) 121:667-673.
138. SPAIDE R, SORENSON J, MARANAN L: Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology (2003) 110:1517-1525.
139. HERIOT W: Corticosteroids for AMD. American Academy of Ophthalmology Annual Meeting (2004) New Orleans, LA; Retina Subspecialty Day supplement:24-25.
140. MOSHFEGHI D, KAISER P, SCOTT I et al.: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol. (2003) 136:791-796.
141. JONAS J, KREISSIG I, HUGGER P et al.: Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br. J. Ophthalmol. (2003) 87(462-8).
142. JONAS J, KREISSIG I, DEGENRING R: Intraocular pressure after intravitreal injection of triamcinolone acetone. Br. J. Ophthalmol. (2003) 87:24-27.
143. CRUM R, SZABO S, FOLKMAN J: A new class of steroids inhibits angiogenesis in the presence of heparin or heparin fragment. Science (1995) 230:1375-1378.
144. CLARK A: AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin. Investig. Drugs (1997) 6:1867-1877.
145. MCNATT L, WEIMER L, YANNI J, CLARK A: Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J. Ocular Pharm. Ther. (1999) 15:413-423.
146. THE ANECORTAVE ACETATE CLINICAL STUDY GROUP: Anecortave acetate as monotherapy for the treatment of subfoveal lesion in patients with exudative age-related macular degeneration (AMD) - interim (month 6) analysis of clinical safety and effecacy. Retina (2003) 23:14-23.
147. CLARK A, MELLON J, Li X et al.: Inhibition of intraocular tumor growth by topical application of the antiangiogenic steroid anecortave acetate. Invest Ophthalmol. Vis. Sci. (1999) 40:2158-2162.
148. PENN J, RAJARATNAM V, COLLIER R, CLARK A: The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis. Sci. (2001) 42:283-290.
149. F 149. THE ANECORTAVE ACETATE CLINICAL STUDY GROUP: Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration - twelve month clinical outcomes. Ophthalmology (2003) 110:2372-2383.
150. CIULLA T, CRISWELL M, DANIS R et al.: Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br. J. Ophthalmol. (2003) 87:1032-1037.
151. NADER N: Clinical trials show promise of intravitreal steroids, other therapies for retinal diseases. Ocular Surgery News (2004) 22(3):28-30.
152. YANG C, KHAWLY J, HAINSWORTH D et al.: An intravitreal sustained release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol. (1998) 116:69-77.
153. PERKINS S, GALLEMORE R, YANG C et al.: Pharmacokinetics of the fluorcinolon/5-fluorouracil codrug in the gas-filled eye. Retina (2000) 20:514-519.